1 Min Read
Dec 8 (Reuters) - Catalyst Pharmaceuticals Inc
* Allowing Adult CMS patients to participate in trial
* "Continue to believe that we will report top-line results from this study in second half of 2017"
* Number of patients increased to approximately 20
* Provides update on its clinical trial for patients with congenital myasthenic syndromes Source text for Eikon: Further company coverage: (Bangalore.email@example.com)